Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

7.46
+0.03500.47%
Volume:131.69K
Turnover:984.00K
Market Cap:492.13M
PE:-1.98
High:7.62
Open:7.58
Low:7.37
Close:7.42
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:0.37
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:6.86
PE(LYR):-1.98

Loading ...

Regenxbio Inc. : Clear Street Cuts Target Price to $32 from $45

THOMSON REUTERS
·
Aug 25

Regenxbio is Maintained at Outperform by Baird

Dow Jones
·
Aug 25

Regenxbio price target lowered to $32 from $45 at Clear Street

TIPRANKS
·
Aug 25

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Ansell (OtherANSLF)

TIPRANKS
·
Aug 25

Top Midday Decliners

MT Newswires Live
·
Aug 25

Morning Movers: Regenxbio sinks following clinical hold on RGX-121

TIPRANKS
·
Aug 24

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Dow Jones
·
Aug 24

Regenxbio Shares Down 25% Premarket After FDA Places Clinical Hold on Co's Gene Therapy for Hunter Syndrome

THOMSON REUTERS
·
Aug 24

Regenxbio reports FDA placed clinical hold on RGX-121

TIPRANKS
·
Aug 24

FDA Places Clinical Hold on Regenxbio RGX-121 Gene Therapy for Hunter Syndrome After Spine MRI Findings

Reuters
·
Aug 24

Regenxbio - Co and Ns Pharma Evaluating Additional Data for Rgx-121

THOMSON REUTERS
·
Aug 24

Regenxbio - FDA Places Clinical Hold on Rgx-121 After Spine Mri Findings

THOMSON REUTERS
·
Aug 24

Regenxbio - Does not Expect to Resubmit Rgx-121 Bla in Near Term

THOMSON REUTERS
·
Aug 24

NASDAQ Trade Halt Halt News Pending at 07:00 Am

Reuters
·
Aug 24

Trump Picks White House Adviser Heidi Overton to Run FDA, Source Says

Reuters
·
Aug 19

Regenxbio Price Target Cut to $23.00/Share from $26.00 by HC Wainwright & Co.

Dow Jones
·
Aug 10

Regenxbio price target lowered to $23 from $26 at H.C. Wainwright

TIPRANKS
·
Aug 10

Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says

MT Newswires Live
·
Aug 08

Regenxbio Cut to Equal-Weight from Overweight by Barclays

Dow Jones
·
Aug 07

Morgan Stanley Adjusts Price Target on REGENXBIO to $18 From $16, Maintains Overweight Rating

MT Newswires Live
·
Aug 07